HC Wainwright set a $6.00 target price on Cancer Genetics (NASDAQ:CGIX) in a research note issued to investors on Tuesday. The firm currently has a buy rating on the medical research company’s stock.
Other equities research analysts have also issued research reports about the company. Maxim Group began coverage on Cancer Genetics in a research report on Thursday, December 7th. They issued a buy rating and a $6.00 target price on the stock. ValuEngine lowered Cancer Genetics from a sell rating to a strong sell rating in a research report on Friday, December 1st. Finally, Zacks Investment Research upgraded Cancer Genetics from a sell rating to a hold rating in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company has an average rating of Hold and an average target price of $5.56.
Shares of Cancer Genetics (NASDAQ:CGIX) traded down $0.05 during midday trading on Tuesday, reaching $1.90. The company had a trading volume of 73,503 shares, compared to its average volume of 182,577. The stock has a market capitalization of $53.33, a price-to-earnings ratio of -2.32 and a beta of 1.10. Cancer Genetics has a 52-week low of $1.70 and a 52-week high of $5.30. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18.
Cancer Genetics (NASDAQ:CGIX) last issued its earnings results on Thursday, November 9th. The medical research company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). Cancer Genetics had a negative net margin of 54.65% and a negative return on equity of 46.21%. sell-side analysts anticipate that Cancer Genetics will post -0.88 earnings per share for the current year.
In related news, Director John Pappajohn acquired 150,000 shares of the stock in a transaction on Friday, December 8th. The shares were acquired at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the transaction, the director now owns 2,781,204 shares in the company, valued at approximately $5,173,039.44. The purchase was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 21.30% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in CGIX. Northern Trust Corp boosted its position in Cancer Genetics by 61.0% in the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after purchasing an additional 12,168 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after buying an additional 197,619 shares during the period. Finally, Granahan Investment Management Inc. MA raised its stake in shares of Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after buying an additional 49,371 shares during the period. Institutional investors and hedge funds own 11.13% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “HC Wainwright Analysts Give Cancer Genetics (CGIX) a $6.00 Price Target” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/19/hc-wainwright-analysts-give-cancer-genetics-cgix-a-6-00-price-target.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.